The BioVent - BIOmarkers for mechanically VENTilated patients cohort study

ISRCTN ISRCTN59376582
DOI https://doi.org/10.1186/ISRCTN59376582
Protocol serial number N/A
Sponsor University Hospital of Basel
Funders Universitätsspital Basel, Gottfried und Julia Bangerter-Rhyner-Stiftung (Switzerland), Universität Basel, Freie Akademische Stiftung (Switzerland)
Submission date
05/07/2013
Registration date
31/10/2013
Last edited
20/04/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The predictive properties of biomarkers in critical care are promising. However, there are few studies and most prospective studies are restricted to specific diseases. The aim of this study is to explore predictors of outcomes in mechanically ventilated patients; to assess short-term and long-term outcomes of mechanically ventilated patients; to identify major events during mechanical ventilation; to identify chronic diseases associated with poor outcomes; to analyze the potential and verify previous results of circulating biomarkers for prognostication in mechanically ventilated patients, patients with ventilator-associated pneumonia and patients with prolonged mechanical ventilation

Who can participate?
Critically ill patients requiring invasive mechanical ventilation for at least 12 hours.

What does the study involve?
This is an observational study. The study does not interfere with treatment. Besides additional blood sampling no interventions are planned. Patients will be assessed at study inclusion, after two, four days, at ICU discharge, at hospital discharge and after one year. Further assessments are scheduled if ventilator-associated pneumonia is suggested or the patient is continuously on invasive mechanical ventilation for 21 days.

What are the possible risks and benefits of participating?
Patients do not experience any direct benefits from the study. However, they contribute to the improvement of medical knowledge in the field. Patients are exposed to a marginal increased risk of anaemia, due to additional blood sampling (approx. 30ml blood, at most 100ml blood during the whole study).

Where is the study run from?
University Hospital Basel, Clinic of Pulmonary Medicine and Respiratory Cell Research (Switzerland)

When is the study starting and how long is it expected to run for?
The study started in 2011 and is expected to last four and half years. The trial will be recruiting participants for approximately three and an half years

Who is funding the study?
University Hospital Basel, Clinic of Pneumology and Respiratory Cell Research. Unrestricted grants are provided by the Gottfried und Julia Bangerter-Rhyner Foundation, University Basel and Freie Akademische Foundation (Switzerland).

Who is the main contact?
Prof. Daiana Stolz

Contact information

Prof Daiana Stolz
Scientific

University Hospital Basel
Pneumology
Petersgraben 4
Basel
4031
Switzerland

Study information

Primary study designObservational
Study designInvestigator initiated and driven prospective observational multicentric longitudinal study
Secondary study designMulti-centre
Study type Participant information sheet
Scientific titleProspective, multicentric, longitudinal study to determine predictors of outcome in mechanically ventilated critically ill patients
Study acronymBioVENT
Study objectivesCirculating biomarkers are able to reliably identify patients with poor outcomes among a critically ill population requiring mechanical ventilation in medical and surgical ICUs.
Ethics approval(s)1. Basel Ethics Committee (Ethikkomission beider Basel 03/2010), Ref.Nr EK 75/10
2. Bellinzona Ethics Committee (Comitato etico cantonale Bellinzona) 12/2011, Rif.CE 2519
3. Lausanne Ethics Committee (Commission cantonale d’ethique Lausanne) 03/2011, Protocole 65/11
4. Medical University of Vienna Ethics Committee (Ethikkomission der Medizinischen Universität Wien) 01/2012, EK Nr. 946/2011
5. Zurich Ethics Committee (Kantonale Ethik-Komission Zürich) 01/2012, KEK-ZH-Nr. 2011-0326
6. Ile de France VI Ethics Committee (Comité de Protection des Personnes Ile de France VI)
Health condition(s) or problem(s) studiedCritically ill patients on invasive mechanical ventilation
InterventionVisit day 0: assessment of baseline characteristics, vitals, venous puncture, subjective estimation of outcome
Visit day 2: vitals, venous puncture, subjective estimation of outcome
Visit day 4: vitals, venous puncture, subjective estimation of outcome
Visit ICU discharge: assessment of complications during ICU stay
Visit hospital discharge: assessment of survival
Visit 1 year: assessment of survival
Visit VAP (if patient develops ventilator associated pneumonia during ICU stay): assessment of VAP parameters, vitals, venous puncture, subjective estimation of outcome
Visit VAP day 4 (four days after development of ventilator associated pneumonia): vitals, venous puncture, subjective estimation of outcome
Visit PMV (if patient on invasive mechanical ventilation for 21 days, prolonged mechanical ventilation) day : vitals, venous puncture, subjective estimation of outcome

Follow-up duration: 12 months.
Intervention typeOther
Primary outcome measure(s)

Crude mortality within 28 days

Key secondary outcome measure(s)

1. Mortality within one year
2. Duration of ICU and hospital stay
3. Duration of mechanical ventilation, ventilation free days, weaning attempts, survival in the subgroups of mechanically ventilated patients, events during mechanical ventilation

Endpoints will be obtained during ICU stay or at scheduled assessments.

Completion date01/04/2015

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexAll
Target sample size at registration1000
Total final enrolment961
Key inclusion criteria1. Critically ill patients at the start of invasive mechanical ventilation
2. Estimated to require continuous ventilatory support for longer than 24 hours or if already ventilated for 12 to maximal 36 hours.
3. 18 years of age or older
Key exclusion criteria1. Pregnancy
2. Patients with pre-existing mental disorder precluding proper informed consent
Date of first enrolment01/04/2011
Date of final enrolment01/04/2015

Locations

Countries of recruitment

  • Austria
  • France
  • Switzerland

Study participating centre

University Hospital Basel
Basel
4031
Switzerland

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 19/04/2023 20/04/2023 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

20/04/2023: Publication reference and total final enrolment added.
24/07/2020: No publications found.